Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • +

      MA04.03 - A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)

      10:55 - 11:00  |  Presenter: Hyun Ae Jung

      • Abstract

      Loading...

  • +

    FP16 - Tumor Biology and Systems Biology: Basic and Translational Science

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

      00:00 - 00:00  |  Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

  • +

    P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P15.01 - Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery

      00:00 - 00:00  |  Presenter: Sehhoon Park

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

      00:00 - 00:00  |  Presenter: Sehhoon Park

      • Abstract

      Loading...

  • +

    IS08 - Industry Symposium Sponsored by Eli Lilly And Company: Personalizing and Optimizing Treatment for Metastatic NSCLC Patients with EGFR Mutations - Is There More We Can Do?

    • 05:45 - 06:45
    • 9/10/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS08.04 - Identifying the Clinical and Disease Characteristics of the High Risk Patient, What Is the Science Telling Us?

      06:15 - 06:25  |  Presenter: Myung-Ju Ahn

      • Abstract

      No abstract available for this presentation

  • +

    MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      MA13.03 - Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial

      17:40 - 17:45  |  Presenter: Jiyun Lee

      • Abstract

      Loading...

  • +

    ES20 - Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials*

    • 20:30 - 21:05
    • 9/14/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Education Session
    • Track: Immunotherapy (Phase II/III Trials)
    *Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.
    • +

      ES20.01 - The Statistical Imperatives of Immunotherapy Research

      20:30 - 20:32  |  Presenter: Mary Redman

      • Abstract

      No abstract available for this presentation

    • +

      ES20.02 - Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer

      20:32 - 20:34  |  Presenter: Sanjay Popat

      • Abstract

      Loading...

    • +

      ES20.03 - Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know

      20:34 - 20:36  |  Presenter: Nick Pavlakis

      • Abstract

      No abstract available for this presentation

    • +

      ES20.04 - Challenges to Expand Who Gets Immunotherapy

      20:36 - 20:38  |  Presenter: Lyudmila Bazhenova

      • Abstract

      No abstract available for this presentation

    • +

      ES20.05 - Live Discussion with Speakers

      20:38 - 21:05

      • Abstract

      No abstract available for this presentation